glp-1 news 2025 november 25 With FDA approval of Wegovy pill, new era of oral weight loss drugs begins Lawmakers Grapple With GLP-1 Access

With last weeks approval of Tirzepatide for obesity, the combined power of a GLP-1 with another gut hormone enhancer (GIP) has shown even more promise with losses of up to an astounding 48 pounds or 21% of body weight at 88 weeks vs

Cheaper obesity medications could come to Canada this summer, as Health Canada reviews generics Having generics that might significantly reduce the price is welcome, obesity physician says Health Canada says it is reviewing nine submissions for generic versions of popular weight loss medications that pharmaceutical experts say could bring down the price

Encourage patients to reach out to their insurance providers to see if weight management medications are covered under their plan and, if so, which medication the plan will pay for

Knowing what to expect and how to handle it can make your journey smoother and more successful

Accumulating evidence from clinical studies, including case-control studies, systematic reviews, and meta-analyses, has consistently demonstrated the limited long-term weight loss efficacy of bariatric surgery in MC4R -deficient patients, which differs significantly from its effects in patients with obesity induced by other genetic variants or non-genetic factors